When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
Craig A. Dionne, PhD, CEO of GenSpera, describes some of the drawbacks associated with common cancer treatments. Many types of drug therapies, like antiangiogenics and immunotherapies, may only…
Mipsagargin (G-202), a new prodrug developed by GenSpera, has a unique mechanism of action that allows it to kill cancer cells without damaging surrounding tissues. Derived from thapsigargin,…
Each week we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
